

Illinois Prescription Monitoring Program

Update - October 2024



Subscribe to follow us @ILPMP on YouTube

View as Webpage

ILPMP Rule Amendments to 77 Illinois Administrative Code 2080 Adopted

Illinois Prescription Monitoring Program amendments to 77 Illinois Administrative Code 2080 have been adopted effective October 8, 2024. Click **here** to view updated Rule.

ILPMP to implement new process

On October 25, 2024, Joint Committe on Administrative Rules (JCAR) published the adopted Rule regarding the process which **Public Act 103-0477**, Section 316.1, shall be implemented. **Adopted Rule**

The ILPMP is working to finalize the Data Sharing Agreements for Integration Vendors and the Memorandum of Understanding for the Healthcare Organizations. Once these documents have been finalized, a more detailed announcement will be published.

Telemedicine Flexibilities on Prescriptions of Controlled Substances to Expire December 2024



Anticipated guidance from the Drug Enforcement Administration (DEA) has been noted as the Office of Information and Regulation Affairs - Office of Management and Budget (OMB) posted a proposed Rule review on October 10, 2024, named "Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications". Any new Rule has to complete this review by OMB before it can be published in the Federal Register. This final rule would be an additional extension of COVID-19 flexibilities for telemedicine prescribing of controlled substances, beyond the current expiration date of December 31, 2024.

More Information

Illinois Medicaid Not Requiring Prior Authorization for Buprenorphine Prescriptions Per Public Act 103-1040

The Illinois Department of Health and Family Services (HFS) has issued a notice to remind healthcare prescribers and pharmacies that buprenorphine no longer requires a prior authorization for age or dosage. This policy applies to the Medicaid fee-for-service (FFS) program and managed care organizations (MCOs). This departmental change was instituted due to a new law that removes prior authorization requirements for higher doses of buprenorphine for treating substance use disorder (SUD). It also protects a physician's freedom to prescribe controlled substances as they determine appropriate and most beneficial to their patients.

Click to review Public Act 103-1040

Educational Resources

Emerging Substances of Misuse

There are numerous concerning substances of misuse becoming more frequently encountered in Illinois. This short animated video briefly discusses these agents, their effects, and potential risks. Brought to you by the Southern Illinois University Edwardsville School of Pharmacy and the Illinois Prescription Monitoring Program.

Xylazine (Rompun)



"Tranq", also known for Xylazine, was found in over 450 drug overdose deaths in Illinois between 2022-2023, with increases in deaths every 6 months.

Xylazine, a non-opioid sedative commonly used in veterinary medicine, has become increasingly prevalent in the unregulated drug supply in the United States. According to the October 2022 Drug Enforcement Administration (DEA) Joint Intelligence Report, xylazine was first noted as an adulterant in Puerto Rico in the early 2000s through DEA reporting and laboratory analysis. Around a decade later, xylazine was documented as a drug of abuse on its own, which has continued to present.

Medetomidine, is also a non-opioid sedative utilized in veterinary medicine, that has been found as a new adulterant in the drug supply in Illinois, particularly in Chicago. It is similar to xylazine; however, it is considered more



The Illinois Department of Human Services' Division of Substance Use Prevention and Recovery created this flyer specifically for people who use drugs.

Please print and share with your patients,

potent. It has no approved use in humans. Multiple drug samples collected from the West Side of Chicago on May 11, 2024, tested positive for elevated levels of medetomidine.

Click button below for more information ...

Veterinary Tranquilzers Provider Education

clients, and peers.

Patient Tranq Flyer

ILPMP Fall Conference Schedule

OCTOBER 28 - 31, 2024

NATIONAL ASSOCIATION OF STATE CONTROLLED SUBSTANCE AUTHORTIES CONFERENCE GREENVILLE, SOUTH CAROLINA



Megan Conant (left) and Jackie DeNardo (right), both IL PMPnow Coordinators, are pictured at the 22nd Annual APRN Midwest Conference that took place on October 18, 2024, in Lisle, Illinois.

Navigating Pain Management, Safe Opioid Prescribing, and Opioid Use Disorder

A three-hour program designed to meet the educational needs for physicians, nurses, and pharmacists. The program is accredited in 6, 30-minute modules.







Continuing Education Program

Navigating Pain Management, Safe Opioid Prescribing, and Opioid Use Disorder

Session 1: Pain taxonomy, pathogenesis, and assessment

Session 2: Developing a patient-centered pain treatment plan

Session 3: Non-opioid analgesics: Evidence and clinical Pearls

Session 4: Opioid analgesics: From A to Z

Session 5: Clinical use of opioids: Safe prescribing and monitoring

Session 6: The exit strategy: When the treatment becomes the problem

Faculty: June Oliver, MSN, APRN/CNS Laura Meyer-Junco, Phon BCPS, FASCP

Camille Dunkley, MD, MHA, MS Noah Cooperstein, MD

Prescriber Register

Pharmacist Register

ILPMP.ORG & IL PMPnow Monthly Data

WEBSITE DATA

SEPTEMBER 2024





289

NEW USERS IN SEPTEMBER



93,478

TOTAL USERS



71,191

TOTAL ILPMP PRESCRIBER USERS



260,773

TOTAL ILPMP WEBSITE REQUESTS



1,806

TOTAL
IL PMPNOW
CONNECTIONS



11,585,224

TOTAL IL PMPNOW REQUESTS

Contact Information

If you have questions about the information that appears in this update or suggestions for future content, please email **dhs.pmp@illinois.gov**. Visit **www.ilpmp.org** for more information.





DIVISION OF SUBSTANCE USE PREVENTION & RECOVERY

The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data on Schedule II-V controlled substances, selected drugs of interest, and other health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.

Illinois Prescription Monitoring Program | 401 North Fourth Street | Springfield, IL 62702 US

<u>Unsubscribe</u> | <u>Update Profile</u> | <u>Constant Contact Data Notice</u>



Try email marketing for free today!